Board of Directors

Mr. Ruhman has more than 30 years of experience in the Brazilian and international capital markets, investment banking and asset management sectors, both as a senior executive and as an entrepreneur in institutions such as Citibank, Indozuez Capital, Banco Matrix and J. Safra.

 

In 2005 he founded RXZ Investimentos, an investment company focused on listed and private equities. In addition, Mr. Ruhman has served on a number of boards, including BR Properties S.A., Tecnisa S.A., Banco J. Safra, Elevadores Atlas S.A, Banco Sudameris Brasil S.A and Albert Einstein Jewish Hospital in Sao Paulo.

 

Currently Mr. Ruhman is a Member of the Weizmann Institute of Science International Board and lives in London. Mr. Ruhman graduated from Escola de Administração de Empresas de São Paulo – Fundação Getulio Vargas in 1979.

Mr. Roberto Ruhman
Chairman of the Board
Mr. Michel Ben Horovitz 
Board Member & CEO

Former CFO of RXZ Investimentos, an investment company focused on listed and private equities. Mr. Horovitz was also a founding partner of two Brazilian Hedge Funds; Skopos Administradora de Recursos and VIX Investimentos. Mr. Horovitz holds a B.S. in Metallurgical Engineering from Universidade de São Paulo.

Former partner and manager of Banco Matrix S.A., where he worked for eight years. Lawyer and partner of law firms for more than ten years, performing in corporate and tax areas, capital markets and estate planning. Graduated from Pontifícia Universidade Católicade São Paulo (PUC/SP), in 1987, with a J.D.

 

Marcelo Bandeira de Mello
Board Member

Bernardo Parnes, founding partner of Investment One Partners, has more than 30 years of experience leading renowned Brazilian and Global financial institutions. He was CEO for Latin America at Deutsche Bank and Chief Country Officer for Brazil. He structured Banco Bradesco BBI S/A, and managed JSI Investimentos Ltda., Joseph Safra's family office. He was president of Merrill Lynch Brazil for more than 10 years, having started his career in finance at Citibank, where he worked for 7 years.

 

Bernardo Parnes
Board Member
Mr. José Roberto Ferraz
Consultant to the Board

J.R. Ferraz is an executive with 25 years of experience in the healthcare industry, having participated in Management Boards in Latin America, USA and Asia-Pacific and led organizations in different therapeutic areas and segments.

Mr. Ferraz is currently General Manager for Galderma Brazil, a leading organization dedicated on improving the lives of people with skin conditions.

Prior to Galderma, Mr. Ferraz held leadership positions with Johnson & Johnson and Janssen Pharmaceuticals. J.R. is a graduate in Business Administration from Fundação Getúlio Vargas (FGV-SP) and post-graduate in International Marketing from the same institution.

Ilana Fogelman, MD, MPH
Scientific Consultant

Dr. Ilana Fogelman is a physician/entrepreneur with 25 years of experience in drug development and regulatory affairs. She currently functions as COO of LifeTech Research (LTR), a due diligence and technology development company, and as VP of Clinical and Regulatory Affairs for C2N Diagnostics, an Alzheimer’s treatment and diagnostic company which she co-founded. She obtained her MD from the University of Sao Paulo, and her MPH from Harvard where she also completed two post-doctoral fellowships. Prior to co-founding LTR in 2003, she worked as a FDA medical reviewer for 6 years, and as a Wall Street biotech analyst for another 3 years.

Eran Blaugrund Ph.D.
Scientific Consultant

Eran Blaugrund earned his PhD in Neuroscience from the Wiezmann Institute of Science in Israel. After post-doctoral studies at Columbia University NY, he spent 20 years with Teva Pharmaceuticals R&D. Dr. Blaugrund started off as a Pharmacology lead, playing an active role in the development and registration of Azilect for treatment of Parkinson's disease. He then set up and managed the Pharmacology department, followed by heading the preclinical project leadership group. Next Dr. Blaugrund headed the project leadership group as vice president for CNS & Pain, a group that was responsible for leading project such as Copaxone, Laquinimod, Azilect, Pridopidine, nuvigil and many others.

 

Dr. Blaugrund is currently serving as CEO of a portfolio company at the FutuRx accelerator and a consultant to Yeda R&D Co. at the Wiezmann Institute of Science.

Professor Alon Chen is the President of Weizmann Institute of Science, Rehovot, Israel and a Director at the Max Planck Institute of Psychiatry, Munich Germany. Prof. Chen also serves as the Head of the Max Planck Society - Weizmann Institute of Science Laboratory for Experimental Neuropsychiatry and Behavioral Neurogenetics.

 

Prof. Chen’s research focuses on the Neurobiology of Stress, particularly the mechanisms by which the brain is regulating the response to stressful challenges and how this response is linked to psychiatric disorders. His lab has made discoveries linking the action of specific stress-related genes with anxiety, depression, social behaviors and metabolism. Prof. Chen and his research team use both mouse genetic models and human patients to ultimately create the scientific groundwork for therapeutic interventions to treat stress-related emotional disorders such as anxiety, post-traumatic stress, anorexia nervosa, and depression.

Eran Blaugrund earned his PhD in Neuroscience from the Wiezmann Institute of Science in Israel. After post-doctoral studies at Columbia University NY, he spent 20 years with Teva Pharmaceuticals R&D. Dr. Blaugrund started off as a Pharmacology lead, playing an active role in the development and registration of Azilect for treatment of Parkinson's disease. He then set up and managed the Pharmacology department, followed by heading the preclinical project leadership group. Next Dr. Blaugrund headed the project leadership group as vice president for CNS & Pain, a group that was responsible for leading project such as Copaxone, Laquinimod, Azilect, Pridopidine, nuvigil and many others.

 

Dr. Blaugrund is currently serving as CEO of a portfolio company at the FutuRx accelerator and a consultant to Yeda R&D Co. at the Wiezmann Institute of Science.

Eran Blaugrund Ph.D.
Scientific Consultant